Table 1.

HLA typing of patient, donor, and allogeneic B-lymphoblastoid cell lines used in this study

BLCLA*B*Cw*DRβ1*DQβ1*DPα1*DPβ1*
Patient 0201/3001 3901/4901 0701/1203 0701/1601 0202/0502 0103 0201/0402 
Donor 3001/3001 3901/4901 0701/1203 0701/1601 0202/0502 0103/0201 0201/0901 
OMW 0201 1401/4501 1601 1301 0603 0201 0101 
AKIBA 2402 5201 1202 1502 0601 0201 0901 
LG-2 2402/3201 3503/4403 0401 0701/1401 0202/0503 0103 0301/0401 
BLCLA*B*Cw*DRβ1*DQβ1*DPα1*DPβ1*
Patient 0201/3001 3901/4901 0701/1203 0701/1601 0202/0502 0103 0201/0402 
Donor 3001/3001 3901/4901 0701/1203 0701/1601 0202/0502 0103/0201 0201/0901 
OMW 0201 1401/4501 1601 1301 0603 0201 0101 
AKIBA 2402 5201 1202 1502 0601 0201 0901 
LG-2 2402/3201 3503/4403 0401 0701/1401 0202/0503 0103 0301/0401 

OMW is on HLA-typed BLCL from the XIth and XIIth International Histocompatibility Workshop. LG-2 as well as patient and donor BLCLs were HLA-typed by standard PCR sequence–specific oligonucleotide probing as described in “Patient, materials, and methods.”

BLCL indicates B-lymphoblastoid cell line.

*

Indicates genomic denomination of HLA alleles determined by molecular typing.

Close Modal

or Create an Account

Close Modal
Close Modal